Every 424B that ADAPTIN BIO INC (APTN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow APTN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APTN filings page.
Adaptin Bio, Inc. (APTN) has filed a prospectus covering the resale by existing selling stockholders of up to 382,400 outstanding shares of common stock plus 38,240 shares issuable upon exercise of placement agent warrants related to a prior private Follow-On Offering. Adaptin will not receive any proceeds from stockholder resales, but will receive cash only if the Placement Agent Warrants are exercised for cash.
The company is an early-stage biotechnology firm developing BRiTE, a platform to deliver immunotherapies and other agents across the blood-brain barrier to treat brain cancers and other CNS and systemic diseases. Adaptin has no commercial revenue, a history of losses, and its auditor has issued a going concern opinion, highlighting dependence on substantial additional capital, particularly to advance clinical trials and expand the pipeline. The prospectus details extensive risks around financing, clinical development, regulatory approvals, manufacturing via third parties, competition, and reliance on licensed intellectual property.
Adaptin Bio, Inc. (APTN) filed a prospectus supplement covering the resale of 1,901,482 shares of common stock and 2,233,083 shares of common stock underlying warrants, all held by selling stockholders. The supplement incorporates new information from a Current Report on Form 8-K dated August 20, 2026.
Adaptin announced that enrollment has opened for a first-in-human, open-label, dose-escalation Phase 1 trial of its BRiTE therapeutic APTN-101 for EGFRvIII-positive glioblastoma, conducted with Duke University and expected to enroll up to 15 adult patients. The company highlights preclinical data showing more than 7-fold increased brain distribution and 70%–80% complete tumor eradication in mouse models. Adaptin’s common stock trades on the OTCQB under “APTN” with a last quoted bid price of $6.27 per share on August 24, 2026.
Adaptin Bio, Inc. (APTN) filed a prospectus supplement for the resale of 1,901,482 shares of common stock by selling stockholders and 2,233,083 shares of common stock underlying warrants held by those stockholders. The supplement incorporates Adaptin’s Quarterly Report for the period ended June 30, 2026.
Adaptin is a preclinical-stage biopharmaceutical company developing its BRiTE platform and lead bispecific T‑cell engager APTN‑101 for glioblastoma and other CNS tumors. For the six months ended June 30, 2026, it reported a net loss of $2,351,408, with an accumulated deficit of $11,643,209 and cash and cash equivalents of $670,488.
Management states these conditions, together with expected ongoing operating losses, raise substantial doubt about Adaptin’s ability to continue as a going concern. The company is funding operations through private placements and warrant exercises and completed multiple 2026 closings under a follow‑on offering at $5.00 per share. Material weaknesses in internal control over financial reporting remain unresolved as of June 30, 2026. As of August 11, 2026, there were 9,233,573 shares of common stock outstanding.
Adaptin Bio, Inc. files a prospectus supplement to register the resale of 1,901,482 shares of common stock and 2,233,083 shares underlying warrants held by selling stockholders, as part of its Form S-1 shelf.
The supplement attaches Amendment No. 1 to the Company’s Form 10-K for the fiscal year ended December 31, 2025, which updates Item 15(b) and Exhibit 23.1 to add an updated auditor consent. The auditor's consent includes an explanatory paragraph stating substantial doubt about the Company’s ability to continue as a going concern.
Shares outstanding were 8,903,229 as of June 11, 2026, and the last quoted OTCQB price was $6.18 per share on June 9, 2026. The registration covers resale by selling holders; proceeds treatment is identified as resale by holders.
Adaptin Bio, Inc. files a prospectus supplement updating its S-1 to register resale of 1,901,482 shares of common stock and notes 2,233,083 shares underlying warrants held by selling stockholders. The supplement incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026, its Form 10-K for fiscal 2025 and an 8-K.
The Company reported $301,309 in cash as of March 31, 2026, a net loss of $1,146,096 for Q1 2026 and an accumulated deficit of $10,437,897. Shares outstanding were stated as 8,851,229 as of May 14, 2026. The supplement updates offering and disclosure materials and should be read with the underlying Prospectus.